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Summary We describe two Li-Fraumeni syndrome families. Family A was remarkable for two early childhood cases of adrenocortical
tumours, family B for a high incidence of many characteristic cancers, including a childhood case of choroid plexus tumour. Using direct
sequencing, we analysed exons 5-9 of the p53 gene in constitutional DNA of individuals from both families and found two novel germline
mutations in exon 5. In family A, we detected a point substitution in codon 138 (GCC to CCC), which resulted in the replacement ofthe alanine
by a proline residue. Family B harboured a single-base pair deletion in codon 178 (CAC to-AC), resulting in a frameshift and premature chain
termination. Three out of six tumours examined from both families, a renal cell carcinoma, a rhabdomyosarcoma and a breast cancer, showed
loss of heterozygosity and contained only the mutant p53allele. The remaining three neoplasms, both adrenocortical tumours and the choroid
plexus tumour retained heterozygosity. Immunohistochemistry with anti-p53 antibody confirmed accumulation of p53 protein in tumours with
loss of heterozygosity, while the remaining tumours were p53 negative. These results support the view that complete loss of activity of the
wild-type p53 need not be the initial event in the formation of all tumours in Li-Fraumeni individuals.
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The Li-Fraumeni syndrome (LFS), first described in 1969 (Li and
Fraumeni, 1969), is a rare dominantly inherited condition that
confers an increased susceptibility to cancer to family members.
These individuals are at a high risk ofdeveloping a large spectrum
of cancers, often with a very early onset. Multiple primary
tumours are also common. The prevalent types of cancer are
soft-tissue sarcomas, osteosarcomas, brain tumours, leukaemias,
adrenocortical carcinomas and premenopausal breast cancer, but
other cancers have also been reported (Li et al, 1988). A family
with a high incidence of cancer is diagnosed as LFS if there is a
proband with a sarcoma under 45 years, one first-degree relative
with cancer under 45 years and another first- or second-degree
relative with cancer under 45 years or a sarcoma at any age
(Li et al, 1988).
In 1990, germline mutations in thep53 tumour-suppressor gene,
which is located on chromosome 17pl3, were identified as a
genetic basis of LFS (Malkin et al, 1990; Srivastava et al, 1990).
Since then, a variety ofgermline mutations have been identified in
approximately 50% of LFS families analysed (Birch et al, 1994a;
reviewed in Malkin, 1994; Eeles, 1995; Frebourg et al, 1995). In
addition, germline p53 mutations have been reported in settings
not conforming to the criteria of classical LFS, for example as in
isolated sarcoma patients (Toguchida et al, 1992) or in individuals
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with multiple tumours (Malkin et al, 1992). Similar to somaticp53
mutations frequently found in sporadic tumours, most of the
germline mutations are missense mutations, clustering in several
conserved domains of the p53 gene (Malkin, 1994; Eeles, 1995).
At present it is not clear whether there is a heterogeneity in LFS
with respect to presence or absence of germline p53 mutations
(Wang et al, 1996). There are cases ofLFS pedigrees, however, in
which the linkage between the cancer susceptibility and the p53
locus has been excluded (Birch et al, 1994b).
In accordance with the concept of p53 being a tumour-
suppressor gene, the tumours in LFS patients are expected to lose
the functional (by the germline mutation unaffected) p53 allele.
There are several single-case reports and one recent larger study
indicating, however, that loss ofheterozygosity is not observed in
a significant fraction ofthese tumours (Varley et al, 1997).
Although genetic diagnosis of germline p53 mutations is
possible in many LFS families, the syndrome is associated with
medical, counselling, psychological and ethical problems (Li et al,
1992). Up to now, no correlation between the type and location of
the germline mutation within the p53 gene and clinical features
has been identified. The exact penetrance and age-, sex- and site-
specific cancerrisk figures forcarriers ofdiverse mutations are not
known. The heterogeneity of the malignancies does not allow a
simple and effective preventive screening, and the treatment of
aggressive tumours associated with LFS is often complicated.
Further studies are therefore needed to generate additional back-
ground knowledge for pilot intervention efforts in carriers of
germlinep53 mutations.
To obtain further data on the nature and implications ofspecific
p53 germline mutations and on the behaviour ofthep53 gene and
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Figure 1 Pedigrees of families A (left) and B (right). Filled symbols represent individuals affected by cancer. Types of cancer are indicated together with the
age of onset in years (in parentheses)
protein in tumours of carriers of these mutations, we analysed in
detail two LFS families and identified two yet unreported germline
mutations in exon 5 of thep53 gene. We also observed interesting
patterns of loss of heterozygosity at the p53 locus and of p53
protein accumulation in tumours in these families.
MATERIALS AND METHODS
Family studies
Families A and B (Figure 1) were referred from the Department of
Medical Genetics, Charles University Hospital, Prague-Motol, and
the Second Radiotherapeutic Clinic, Paskov, respectively, based
on the unusual clustering of cancer cases. Both families were
offered counselling and were asked for consent before sampling
and testing. The diagnoses of tumours were confirmed through
hospital and pathology reports and death certificates. Independent
confirmation of histology was possible for the tumours of A-II.1,
A-IV.I (2x), A-IV.2, B-III.2 and B-IV.1.
PCR
Genomic DNA was isolated from peripheral blood lymphocytes
using standard methods (Baas et al, 1984). Exons 5 and 6 ofthep53
gene were amplified by primers e56F (TGCCCTGACTT''7CAAC-
TCTGTC) and e56B (CCACTGACAACCACCCTTAACC), exon 7
by primers e7F (AAGGCGCACTGGCCTCATCTTG) and e7B
(CCAGTGTGCAGGGTGGCAAGTG) and exons 8 and 9 by
primers e89F (GACCTGAT'I'CCTTACTGCCTC) and e89B
(CCACTTGATAAGAGGTCCCAAG). The 50-,ulpolymerase chain
reaction (PCR) contained 30pmol of each primer, 250 ,UM of each
dNTP, 50-100 ng ofgenomic DNA and 0.2 units ofSuper Taq DNA
polymerase (Stehelin & Cie) in a buffer recommended by the
supplier. The reaction mixture was subjected to 35 cycles ofdenatu-
ration at 93°C for 60 s, annealing at 65°C for 45 s and extension at
75°C for 90 s. The annealing and extension temperatures for primers
e89F and e89B were lowered to 59°C and 72°C respectively. DNA
from archival paraffin-embedded tissues was isolated using the
microwave method (Banerjee et al, 1995). Shorter PCR products
spanning the mutation sites were amplified using primers e56F and
c138B (TGCTGTGACTGCTTGTAGATGG) in samples from
family A and e56F and e5B (TCAGTGAGGAATCAGAGGCCTG)
in samples from family B. In these cases, the number ofPCR cycles
was increased to 45.
Sequencing
The PCR products were purified from agarose gels using
QIAquick Gel Extraction Kit (QIAGEN). Cycle-sequencing of
both strands (Carothers et al, 1989) was performed using either of
the two primers used in PCR with dye terminator chemistry and
AmpliTaq FS (Perkin-Elmer). The products were analysed on an
ABI 373A sequencer.
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Table 1. Summary of results of molecular and immunohistochemical studies in families A and B
Germline mutation Tumour
Nucleotide Amino acid Loss of wt p53 Staining
Family Codon change change Subject Blood Type p53 Allele positive cells (%)
A 138 GCC > CCC Ala > Pro A-11.1 - Renal cell carcinoma Yes 35-47
A-111.2 wt/mut - - -
A-IV.1 wt/mut Adrenocortical carcinoma No 0
Rhabdomyosarcoma Yes 28-36
A-IV.2 wt/mut Adrenocortical adenoma No Rare cells
B 178 CAC > -AC Frameshift B-111.2 wtVmut Breast cancer Yes 90-95
B-IV.1 - Choroid plexus tumour No 0
wt, Wild type allele; mut, mutant allele. Loss of the wt allele was deduced from sequencing gels.
p53 Staining
Immunohistochemistry using the p53 antibody DO-7 (Dako)
diluted 1:50 was performed on paraffin-embedded tumour material
using a high-performance detection system APAAP (BioGenex).
The primary serum was substituted by non-immune serum for
negative controls. Positive controls were provided with each set of
antibodies. The slides were counterstained with Mayer's haema-
toxylin.
RESULTS
Identification of germline mutations
The pedigrees of families A and B showed clustering of cancer
cases, with a high proportion of tumours being characteristic for
LFS and often occurring at a young age (Figure 1). Both families
conformed to the criteria of classical LFS (Li et al, 1988).
Peripheral blood lymphocyte DNA samples from individuals
A-III.2, A-IV.1, A-IV.2 and B-III.2 were available. The results
of the search for germline p53 mutations in these samples are
summarized in Table 1.
In family A, the direct sequencing of PCR products generated
from exons 5-9 ofthep53 gene from lymphocyte DNA ofindivid-
uals A-III.2, A-IV. 1 and A-IV.2 revealed heterozygosity for a G to
C transversion in the first position of codon 138. The codon
change from GCC to CCC resulted in an amino acid change from
alanine to proline (Figure 2).
The sequence analysis of constitutional DNA of individual
B-III.2, the only living affected member of family B, revealed
heterozygous deletion of one C nucleotide in the first position of
codon 178 ofthep53 gene. The frameshift caused by this deletion
results, if translated, in the incorporation of 68 illegitimate amino
acid residues and premature chain termination (Figure 2).
Analysis of tumours
Archival tumour samples from the renal cell carcinoma ofA-II.1,
adrenocortical tumours of A-IV. 1 and A-IV.2, rhabdomyosarcoma
of A-IV.1, breast cancer of B-III.2 and brain tumour of B-IV.1
were available for independent confirmation of the diagnoses as
well as for DNA analysis and immunohistochemistry. The results
ofthese studies are summarized in Table 1.
The renal cell carcinoma of patient A-II.1 had a typical clear-
cell cytology and displayed a solid and tubular growth pattern.
Sequencing of the tumour DNA isolated from archival samples
showed loss of the wild-type p53 allele at the site of germline
mutation in codon 138 of the p53 gene. Immunohistochemical
detection of the p53 protein with antibody DO-7 in this tumour
revealed a strong to moderate staining in a high proportion of
tumour cells (Figure 3A). Similar to all other tumours examined in
family A, theimmunohistochemical p53 positivity was confined to
tumour cell nuclei. Stromal cells, such as vascular endothelium,
were negative in all tumours examined.
The adrenocortical tumour of patient A-IV.1 was grossly
encapsulated, measuring 45x40x20 mm. It was composed oflarge
polygonal cells with marked nuclear irregularities, growing in
diffuse sheets and showing numerous mitotic figures, including
multipolar mitoses (mitotic count averaged 8/10 high-power fields
(HPF), using objective 40x and eyepiece 12.5x). There were
microscopic foci of capsular invasion by the tumour into the
surrounding adipose tissue. Vascular invasion was not observed.
The tumour was hormonally active causing virilization. It was
diagnosed as an adrenocortical carcinoma according to the criteria
outlined by Weiss et al (1984) and van Slooten et al (1985). The
tumour retained heterozygosity in codon 138 of thep53 gene and
p53 staining was negative.
The soft-tissue tumourofthe abovepatient was apredominantly
spindle-cell sarcoma with occasional tadpole and round rhabdo-
myoblasts positive fordesmin, sarcomeric actin and myoglobin. It
was classified as an embryonal rhabdomyosarcoma. It showed loss
ofthe wild-type allele in codon 138 (Figure 2) and strong nuclear
staining with the anti-p53 antibody (Figure 3B).
The adrenocortical tumour ofpatient A-IV.2 was encapsulated,
measuring 50x5Ox40mm. Light microscopy revealed solid
trabecular and solid alveolar pattems. The tumour cells showed
moderate nuclear atypia. The mitotic count was low (<1/10 HPF).
No capsular or vascular invasion was found. The tumour was
hormonally active with virilizing effects and was classified as an
adrenocortical adenoma. This tumour did not show loss of
heterozygosity in codon 138. It was generally p53 negative,
although rare scattered foci of tumour cells with positive nuclear
p53 staining were observed (Figure 3C).
The breast cancer ofthe patient B-III.2 from family B was clas-
sified as ductal infiltrating carcinoma. It showed loss ofheterozy-
gosity in codon 178 ofthep53 gene and displayed only the mutant
allele (Figure 2). The p53 immunohistochemistry revealed a strong
staining of most tumour cells (Figure 3D). Non-neoplastic epithe-
lial cells of breast ducts and lobules as well as stromal cells were
negative.
The choroid plexus carcinoma of patient B-IV.1 was character-
ized by marked cellular atypias with foci of solid growth pattern
besides more typical papillary areas. The tumour DNA retained
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Figure 2 Sequence analysis of regions harbouring germline p53mutations in families A (left) and B (right) compared with the wild-type sequence.
Heterozygosity in peripheral blood DNA samples is indicated by two base symbols in one position. The amino acid sequence differences from wild type are
indicated in red below the examples of sequences derived from tumours with loss of the wild-type allele
heterozygosity in codon 178, and the immunohistochemistry with
anti-p53 antibody yielded a negative result.
DISCUSSION
Both families A and B conform to the criteria ofclassical LFS and
show furthertypical features ofthis syndrome (Li et al, 1988). Our
analysis identified germline mutations in the p53 gene in both
families studied.
Family A is remarkable because of the occurrence of two cases
of early childhood adrenocortical tumours in two sisters (A-IV.1
and A-IV.2) and a childhood sarcoma in the first child. The renal
cell carcinoma of the grandfather of the two children (A-II.1) is a
rare, but already reported cancer in LFS (Li et al, 1988). The pres-
ence of rhabdomyosarcoma and adrenocortical tumours in young
children point to a high risk of carrying a germline p53 mutation
(Birch et al, 1994a). Indeed, agermline mutation in codon 138 was
identified in both girls and their mother (A-III.2). The mother is
now 30 and cancer free, but is at a very high risk of developing
breast cancer. The outbreak of early childhood cancer in children
from a 30-year-old asymptomatic carrier whose ancestors devel-
oped cancer between 37 and 45 years of age may possibly have
been influenced in the last generation by a change in the genetic
background on which the germline p53 mutation exists in this
pedigree.
The functional consequences ofthe missense mutation in codon
138 remain to be determined, but several lines ofevidence support
its causal role in the LFS in family A. Codon 138 is located in the
DNA binding domain of the p53 protein (Cho et al, 1994). The
alanine residue in position 138 is located in the conserved domain
II. of p53 and shows absolute evolutionary conservation in p53
sequences ofall vertebrate and one mollusc species reported so far
(Soussi and May, 1996). Owing to the cyclic nature ofproline, the
replacement of alanine by proline may have profound conse-
quences on the protein structure. No polymorphisms have been
described for codon 138 (De Vries et al, 1996). A different
germline mutation of this codon, GCC to TCC, replacing alanine
by serine, was described in a family with gliosarcoma and non-
Hodgkin's lymphoma (Kyritsis et al, 1994). The databases of
somatic p53 mutations in tumours list 13 tumours with missense
codon 138 mutations, five ofwhich are identical with the mutation
seen in family A (De Vries et al, 1996; Hollstein et al, 1996). In
family A itself, the mutation segregates with cancer susceptibility,
and two tumours analysed show loss of the wild-type allele while
retaining the mutant allele.
Family B represents a textbook example of LFS. The occur-
rence of choroid plexus tumour in B-IV.1 supports the view that
this tumour may also be frequent in LFS (Li and Fraumeni, 1994).
The frameshift germline p53 mutation identified in this family
very likely abolishes the function ofthe mutant allele. The deletion
in codon 178 occurs in a contiguous stretch of five C nucleotides,
which represents one of the hot spots for somatic insertion-
deletion mutations in p53 (Greenblatt et al, 1996). An identical
mutation also plays a role in sporadic cancer and was reported as a
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Figure 3 Immunohistochemical detection of the p53 protein showing nuclear positivity in tumour cells. The cell nuclei are counterstained with haematoxylin.
(A) Renal cell carcinoma of patient A-11.1. The intensity of staining varies, being generally strong to moderate. Magnification x350. (B) Embryonal
rhabdomyosarcoma of A-IV.1. A spindle-cell area with positive nuclear staining. Magnification x350. (C) Adrenocortical adenoma of A-IV.2. One of the rare foci
of tumour cells positive for the p53 protein (arrow). The staining is homogeneous and obscures the chromatin pattern seen in negative tumour cell nuclei
counterstained by haematoxylin. Magnification x350. (D) Infiltrating ductal breast carcinoma of patient B-111.2. Strong positivity forp53 in most cell nuclei.
Magnification x225.
somatic mutation in ten different tumours (De Vries et al, 1996;
Hollstein et al, 1996). Translation ofthe mutant allele cangive rise
to a truncated protein. There are several reports showing that
mRNA corresponding top53 alleles with premature stop codons is
absent from cells harbouring these mutations in a heterozygous
state (Felix et al, 1993; Horio et al, 1994: Stolzenberg et al, 1994).
Frameshift mutations caused by insertion-deletion events or
splicing mutations represent approximately only 10% ofgermline
p53 mutations reported so far (Malkin, 1994; Eeles, 1995).
Individuals or families carrying these mutations do not show any
particular features compared with those harbouring diverse
missense mutations. Although it is tempting to speculate that the
mutation in family B has a very high penetrance and that the
cancer onset is relatively early, more data are needed to establish
possible genotype-phenotype correlations in LFS.
Our studies ofpatterns ofloss ofheterozygosity at thep53 locus
and of protein p53 accumulation yielded interesting results. Two
out offour tumours analysed in family A and one oftwo in family
B showed loss ofthe wild-typep53 allele at the site ofthe germline
mutation, while the remaining tumours retained heterozygosity.
This pattern is in agreement with published data, in which the frac-
tion of tumours with loss of heterozygosity ranges from 44% to
69% (Varley et al, 1997). Our results are further supported by
immunohistochemistry with the anti-p53 antibody, which indi-
cated the accumulation ofthe p53 protein in tumours that have lost
the wild-type allele. With the exception ofrare foci ofp53-positive
cells in the adrenocortical tumour of A-IV.2, no accumulation of
p53 was detected in tumours thatretained heterozygosity atthe site
of germline mutation. Although a second independent somatic
mutation disabling the wild-type p53 allele in these tumours
cannot be ruled out, the above results suggest that wild-typep53 is
not inactivated here.
It is interesting that the tumour types in which neither loss of
heterozygosity nor positive p53 staining were observed belong to
early childhood tumours characteristic ofLFS. While the sporadic
adrenocortical tumours are most common between the fifth and
seventh decade oflife, a substantial fraction ofchildhood cases of
this tumour belong to LFS families. Similarly, choroid plexus
tumour may be another specific early manifestation ofLFS. It may
be possible that the initial event in the formation ofthese tumours
in LFS individuals is not the complete loss ofactivity of the wild-
typep53, but that they may be initiated in heterozygous cells by a
p53 dosage effect during a period that is critical for the particular
tissue or cell type. The post-natal regression of the fetal adrenal
cortex and a progressive remodelling of the fetal zone into the
definitive zonae fasciculata andreticularis (Symington, 1982) may
be one such critical point.
The identification of germline p53 mutations is at present
accompanied by counselling and medical problems (Li et al,
1992). The situation is slightly different for those members of
cancer-prone families who are already affected by cancer (A-IV.1,
A-IV.2, B-III.2) or who are aware of their obligate carriership
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(A-II.2). The detection of germline p53 mutations in these indi-
viduals should lead to an offer for preventive screening measures
and should be taken into account when selecting therapeutic strate-
gies. The screening and therapeutic approaches should reflect the
possible susceptibility to secondary iatrogenic cancers in LFS
individuals and a limited response of tumours harbouring p53
mutations to certain agents. In light of current limited possibilities
ofeffective preventive screening and effective therapy of tumours
associated with LFS, however, any presymptomatic diagnosis in
individuals at 50% risk (A-ILI.3, A-III.4) should be preceded by
exhaustive and individual counselling. Testing ofchildren (B-IV.2)
represents a particular problem (Li et al, 1992).
In summary, the two LFS families with two novel germline p53
mutations showing specific patterns of loss of heterozygosity at
the p53 locus and of p53 accumulation in tumours add to the
currently still expanding body of knowledge of this syndrome.
Studies of LFS contribute to the general understanding of the
processes ofcarcinogenesis. A betterunderstanding ofcorrelations
between genotype and phenotype in LFS will eventually lead to
the better management strategies that are needed for this rare but
devastating disorder.
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